Verastem

VSTM

Market cap $497M

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of emplo.

Verastem, Inc. is downgraded from Strong Buy" to Buy following discontinuation of its RAMP-203 G12C NSCLC study. VSTM pivots focus to VS-7375, an oral KRAS G12D "ON/OFF" inhibitor, with promising early efficacy and safety data in KRAS G12D NSCLC patients. Upcoming interim phase 1/2a U.S. data for VS-7375 in KRAS G12D solid tumors, expected 1H 2026, is a major catalyst.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) it will discontinue the trial to focus resources on clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. The.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will join the Company's executive leadership team, while John Johnson, a board member since 2020, has been appointe.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida. A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company's website at www.vera.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced underwritten public offering of 8,543,794 shares of its common stock at an offering price to the public of $7.25 per share, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,870,000 shares of its common stock at.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Verastem Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock sold in the offering on the.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in November: Guggenheim Healthcare Conference 2025: Fireside chat on Tuesday, November 11 at 1:00 pm ET Jefferies Global Healthcare Conference in London: Fireside chat on Wednesday, November 19 at 2:30 pm.

Verastem, Inc. ( VSTM ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Julissa Viana - Vice President of Corporate Communications & Investor Relations Daniel Paterson - President, CEO & Director Matthew Ros - Chief Operating Officer Michael Crowther - Chief Commercial & Strategy Officer Daniel Calkins - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Justin Zelin - BTIG, LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Yuan Zhi - B.

Verastem (VSTM) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.6 per share a year ago.